Alan Rong

3.6k total citations · 1 hit paper
28 papers, 1.0k citations indexed

About

Alan Rong is a scholar working on Oncology, Statistics and Probability and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alan Rong has authored 28 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Statistics and Probability and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alan Rong's work include Colorectal Cancer Treatments and Studies (14 papers), Statistical Methods in Clinical Trials (11 papers) and Lung Cancer Treatments and Mutations (6 papers). Alan Rong is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Statistical Methods in Clinical Trials (11 papers) and Lung Cancer Treatments and Mutations (6 papers). Alan Rong collaborates with scholars based in United States, Belgium and France. Alan Rong's co-authors include Kelly S. Oliner, Marc Peeters, Andrés Cervantes, Timothy Price, Yevhen Hotko, Michel Ducreux, Thierry André, Florian Lordick, Jennifer Gansert and Alberto Sobrero and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Alan Rong

25 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

2010 755 citations Marc Peeters, Timothy Price et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan Rong United States	10	850	378	269	235	166	28	1.0k
B. Lueza France	10	595 0.7×	302 0.8×	234 0.9×	143 0.6×	140 0.8×	20	790
Andrew Strickland Australia	12	891 1.0×	436 1.2×	278 1.0×	210 0.9×	170 1.0×	31	1.1k
Seta Shahin United States	8	812 1.0×	319 0.8×	145 0.5×	186 0.8×	127 0.8×	13	948
Clemens Gießen Germany	20	944 1.1×	548 1.4×	271 1.0×	288 1.2×	166 1.0×	46	1.1k
Roger Sidhu United States	13	715 0.8×	388 1.0×	248 0.9×	152 0.6×	165 1.0×	29	904
M. Rother Canada	5	1.3k 1.5×	577 1.5×	362 1.3×	367 1.6×	218 1.3×	8	1.4k
Allert H. Vos Netherlands	8	1.3k 1.6×	542 1.4×	325 1.2×	314 1.3×	290 1.7×	11	1.6k
Artur Katz Brazil	15	604 0.7×	360 1.0×	135 0.5×	50 0.2×	326 2.0×	59	998
Jenny F. Seligmann United Kingdom	14	1.2k 1.4×	440 1.2×	424 1.6×	277 1.2×	272 1.6×	61	1.6k
M. E. Vega-Villegas Spain	9	951 1.1×	562 1.5×	180 0.7×	226 1.0×	106 0.6×	17	1.2k

Countries citing papers authored by Alan Rong

Since Specialization

Citations

This map shows the geographic impact of Alan Rong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Rong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Rong more than expected).

Fields of papers citing papers by Alan Rong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Rong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Rong. The network helps show where Alan Rong may publish in the future.

Co-authorship network of co-authors of Alan Rong

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Rong. A scholar is included among the top collaborators of Alan Rong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Rong. Alan Rong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Takeda, Kentaro, et al.. (2024). A basket trial design based on constrained hierarchical Bayesian model for latent subgroups. Journal of Biopharmaceutical Statistics. 35(2). 271–282.

Takeda, Kentaro, et al.. (2023). Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs. Therapeutic Innovation & Regulatory Science. 57(4). 728–736. 2 indexed citations

Liu, Shufang, Kentaro Takeda, & Alan Rong. (2022). An adaptive biomarker basket design in phase II oncology trials. Pharmaceutical Statistics. 22(1). 128–142. 2 indexed citations

Takeda, Kentaro, Shufang Liu, & Alan Rong. (2021). Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers. Statistics in Medicine. 41(2). 298–309. 8 indexed citations

Takeda, Kentaro, Qing Xia, Shufang Liu, & Alan Rong. (2021). TITE‐gBOIN: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding accounting for toxicity grades. Pharmaceutical Statistics. 21(2). 496–506. 12 indexed citations

Liu, Shufang, Chenghao Chu, & Alan Rong. (2018). Weighted log‐rank test for time‐to‐event data in immunotherapy trials with random delayed treatment effect and cure rate. Pharmaceutical Statistics. 17(5). 541–554. 19 indexed citations

Diao, Guoqing, Jun Dong, Donglin Zeng, et al.. (2018). Biomarker threshold adaptive designs for survival endpoints. Journal of Biopharmaceutical Statistics. 28(6). 1038–1054. 10 indexed citations

Chen, S., et al.. (2018). Estimation of delay time in survival data with delayed treatment effect. Journal of Biopharmaceutical Statistics. 29(2). 229–243. 7 indexed citations

Gao, Fei, Jun Dong, Donglin Zeng, Alan Rong, & Joseph G. Ibrahim. (2017). Pattern mixture models for clinical validation of biomarkers in the presence of missing data. Statistics in Medicine. 36(19). 2994–3004.

10.

Diao, Guoqing, Donglin Zeng, Joseph G. Ibrahim, et al.. (2017). Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects. Journal of Biopharmaceutical Statistics. 27(6). 933–944. 3 indexed citations

11.

Hecht, J. Randolph, Jean‐Yves Douillard, Lee S. Schwartzberg, et al.. (2015). Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treatment Reviews. 41(8). 653–659. 45 indexed citations

12.

Xu, Tu, Yixin Fang, Alan Rong, & Junhui Wang. (2015). Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy. BMC Medical Research Methodology. 15(1). 94–94. 34 indexed citations

13.

Sidhu, Roger, Alan Rong, & Steve Dahlberg. (2013). Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials. Clinical Cancer Research. 19(5). 969–976. 36 indexed citations

14.

Oliner, Kelly S., Jean‐Yves Douillard, Salvatore Siena, et al.. (2013). Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC). Annals of Oncology. 24. iv23–iv24. 2 indexed citations

15.

Oliner, Kelly S., Jean‐Yves Douillard, Salvatore Siena, et al.. (2013). Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 31(15_suppl). 3511–3511. 42 indexed citations

16.

Douillard, Jean‐Yves, Marc Peeters, Alan Rong, et al.. (2012). Effect of Post-Protocol Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal AntiBody (MAB) Therapy on Survival Outcomes in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Treated with Panitumumab (PMAB) Plus Chemotherapy. Annals of Oncology. 23. ix194–ix195. 1 indexed citations

17.

Sidhu, R., Alan Rong, & Steve Dahlberg. (2011). Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 29(15_suppl). 3617–3617.

18.

Peeters, Marc, Timothy Price, Andrés Cervantes, et al.. (2010). Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 28(31). 4706–4713. 755 indexed citations breakdown →

19.

Peeters, Marc, Timothy Price, Yevhen Hotko, et al.. (2009). 14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). European Journal of Cancer Supplements. 7(3). 10–10. 23 indexed citations

20.

Singer, Jack W., Daniel J. Weisdorf, Teresa Gentile, et al.. (2004). Palifermin reduces severe oral mucositis (OM), improves patient quality of life, and reduces health resource use in patients with hematologic malignancies receiving high-dose chemotherapy (HDCT) and total body irradiation (TBI) with autologous peripheral blood stem cell (PBSC) support: results from a phase III trial. Biology of Blood and Marrow Transplantation. 10. 31–31. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact